Rhone-Poulenc Rorer Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Strasbourg France (1990)
Status: Acquired by Aventis (1999) → now Sanofi-Aventis (2004)

Organization Overview

First Clinical Trial
1999
NCT00148070
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2000

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (1)

Key: Rhone-Poulenc Rorer (0) Acquired (1)

procaine benzylpenicillin (novocaine) (1 trial)

Drugs in Phase 3 Trials (2)

Key: Rhone-Poulenc Rorer (0) Acquired (2)

atorvastatin (lipitor) (1 trial)

levocarnitine (carnitor) (1 trial)

Drugs in Phase 2 Trials (2)

docetaxel (taxotere) (1 trial)

erythromycin (ilosone) (1 trial)

Drugs in Phase 1 Trials (4)

Key: Rhone-Poulenc Rorer (1) Acquired (3)

aldesleukin (Proleukin) (1 trial)

garlic (2 trials)

spiramycin (2 trials)

zidovudine (retrovir) (1 trial)

Drugs in Other Trials (14)

Key: Rhone-Poulenc Rorer (1) Acquired (13)

bifidobacterium lactis (1 trial)

c6 ketone di-ester (2 trials)

enoxaparin (lovenox) (1 trial)

erythritol (1 trial)

fiber (1 trial)

gingerol (1 trial)

ketone monoester (1 trial)

maltodextrin (1 trial)

pentamidine (pentam) (5 trials)

sc-fos (1 trial)

thiethylperazine (torecan) (1 trial)

thiocarb (2 trials)

totum-63 (1 trial)

turmeric (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Cryptosporidiosis (Phase 1)

Diarrhea (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 26
  • # of Trial APIs: 23